Cardiac ArrestPhase 2/3NCT00282373
Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients
A Phase 2/3 study testing mild hypothermia in people with Cardiac Arrest, run by Medivance, Inc. at 6 sites in United States.
Trial summary
The primary objectives of this study are to determine the safety and feasibility of inducing mild hypothermia using a non-invasive thermoregulatory device, the Medivance Arctic Sun Temperature Management System, in patients resuscitated after cardiac arrest. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiac Arrest
- What is being tested?
- mild hypothermia
- Type of treatment
- Medical device
- How many people
- 64 participants
- Where
- 6 sitesUnited States
- Study dates
- Nov 2004to Sep 2007
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female patients ≥ 18 years.
- Witnessed out-of-hospital cardiac arrest of presumed cardiac origin in which the initial rhythm is ventricular fibrillation, ventricular tachycardia, pulseless electrical activity (PEA) or asystole.
- First attempt at resuscitation (ACLS or CPR) by emergency medical personnel initiated within 15 minutes of collapse.
- Restoration of spontaneous circulation (ROSC) within 60 minutes of collapse.
- Time from restoration of spontaneous circulation to initiation of cooling is ≤ 6 hours.
- Informed consent provided by authorized representative/family member.
Who cannot join
- Temperature of less than 35C on admission.
- Comatose or vegetative state prior to cardiac arrest.
- Positive pregnancy test.
- Purposeful response to verbal commands after ROSC and prior to initiation of hypothermia.
- Evidence of hypotension (MAP<60) for more than 30 minutes after ROSC and prior to initiation of hypothermia.
- Evidence of hypoxia (oxygen saturation<85% despite supplemental oxygen) for more than 15 minutes after ROSC and prior to initiation of hypothermia.
Show all 17Show fewer
- Terminal illness that preceded the arrest (life expenctancy < 1 year).
- Patients experiencing cardiogenic shock.
- Patients continuing to experience refractory ventricular arrhythmias at the time of enrollment.
- Patients receiving 2 or more high dose vasopressors.
- Active bleeding or known preexisting coagulapathy.
- Patient history of cold agglutinin disease.
- Patient history of Raynaud's Disease.
- Patient history of Sickle Cell disease.
- Evidence of compromised skin integrity or irregularities (such as urticaria, rash, lacerations, burns, abrasions.
- Patient weight > 114 kg (250 lbs) or < 50 kg (110 lbs)
- Enrollment in another therapeutic study.
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United States6 sites
Johns Hopkins - Bayview Medical Center
Baltimore, Maryland, 21224
Ohio State University Medical Center
Columbus, Ohio, 43210
University of Colorado Health Science Center
Denver, Colorado, 80262
Virginia Commonwealth University Medical Center
Richmond, Virginia, 23298
William Beaumont Hospital
Royal Oak, Michigan, 48073
University of Arizona Medical Center
Tucson, Arizona, 85724
About this study
Official title: Randomized Controlled Pilot Study: Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients Using Traditional Surface Cooling Techniques vs. the Medivance® Arctic Sun® System
The primary objectives of this study are to determine the safety and feasibility of inducing mild hypothermia using a non-invasive thermoregulatory device, the Medivance Arctic Sun Temperature Management System, in patients resuscitated after cardiac arrest.
Read the detailed description
Extensive research has been conducted in the use of mild hypothermia as a neuroprotectant in acute brain injury in animal models with studies having been initiated as far back as the 1950's. However, little work had been done in the area of therapeutic hypothermia and cardiac arrest.
In the early 80's, the Pittsburgh group resurrected the work with the induction of hypothermia in animals. The discovery of mild resuscitative hypothermia provided evidence that the main mechanism by which hypothermia can help resuscitate the brain after normothermic cardiac arrest is a synergistic effect of the suppression of deleterious chemical cascades, energy loss depolarization, calcium influx, excitotoxicity, free radical reactions, membrane failure, DNA fragmentation, and damage to the mitochondria).
Recently, the study "Mild hypothermia to improve the neurologic outcome after cardiac arrest" from the Hypothermia After Cardiac Arrest Study Group (New Engl J Med 2002;346:549-556) reported the results of a multicenter randomized controlled clinical trial that evaluated the effect of mild systemic hypothermia on mortality and functional outcome after resuscitation from out-of-hospital cardiac arrest due to ventricular fibrillation or tachycardia. Two hundred and seventy three patients were randomly assigned to standard normothermic or hypothermic management. Cooling to a target core body temperature of 32ºC to 34ºC was accomplished with the use of a specialized bed which delivers cold air over the entire body. Temperature was maintained in the target range for 24 hours after the start of cooling, followed by passive rewarming over 8 hours. Outcome was assessed at 6 months with a five point scale similar to the Glasgow Outcome Scale, dichotomized to classify independent patients with minimal or moderate disability to those who were dependent and severely disabled, vegetative, or dead. The results demonstrated a favorable neurological outcome in 55% of the 136 patients treated with hypothermia, compared to 39% of the 137 patients treated with normothermic management (risk ratio 1.40, 95% confidence interval 1.08 to 1.81, P=.009). . Mortality was also reduced with hypothermic management, from 41% in the hypothermia group to 55% in the normothermia group (risk ratio 0.74, 95% confidence interval 0.58 to 0.85, P=.02). In 19 patients (14%), the target temperature could not be reached. Complications did not differ significantly between the two groups, although there were trends toward increased rates of sepsis and bleeding with hypothermia.
Based upon the body of published evidence to date, the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR) made the following recommendations in October 2002 (Resuscitation 57 (2003) 231-235):
- Unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest should be cooled to 32-34°C for 12 -24 hours when the initial rhythm is ventricular fibrillation (VF).
- Such cooling may also be beneficial for other rhythms or in-hospital cardiac arrest
The study is a prospective, randomized, multi-center, pilot study of the Arctic Sun System used as adjunctive therapy in patients resuscitated post cardiac arrest.
Patients who meet the inclusion criteria and for whom informed consent has been provided by an authorized representative/family member will be randomly assigned to either the control group (traditional cooling blankets and ice) or the experimental group (Arctic Sun Temperature Management System).
Patients will be cooled to a target range of 33.5°C to 33.9°C. The patient cooling will continue for 24 hours (from the initiation of cooling) and then gradually rewarmed to 36.0°C over approximately 6 to 12 hours.
- Conditions
- Cardiac Arrest
- Being tested
- mild hypothermia
- Medical subject headings
- Heart Arrest
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mild hypothermiaDevice
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility -patient temperature below 34C within 4 hours
Feasibility -maintain patient target temperature for 24 hrs
Safety - serious adverse events, mortality
Secondary outcomes (1)
Effectiveness - neurological outcome measured by OPC/CPC
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2006 (estimated)
- Study startNov 2004
- Study completionSep 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardiac ArrestStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 64 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medivance, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Kennon Heard, M.D., Principal investigator, University of Colorado, Denver
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00282373
- Sponsor's protocol ID
- RESCUE
- Status last verified
- Sep 2007
- First submitted
- 24 Jan 2006
- Last updated
- 11 Sep 2007
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Heard KJ, Peberdy MA, Sayre MR, Sanders A, Geocadin RG, Dixon SR, Larabee TM, Hiller K, Fiorello A, Paradis NA, O'Neil BJ. A randomized controlled trial comparing the Arctic Sun to standard cooling for induction of hypothermia after cardiac arrest. Resuscitation. 2010 Jan;81(1):9-14. doi: 10.1016/j.resuscitation.2009.09.015. Epub 2009 Oct 24.
PubMed 19854555
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Pilot Study: Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients Using Traditional Surface Cooling Techniques vs. the Medivance® Arctic Sun® System
- ClinicalTrials.gov ID
- NCT00282373
- Acronym / sponsor ID
- RESCUE
- Conditions
- Cardiac Arrest
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (estimated)
- Lead sponsor
- Medivance, Inc.Industry (pharma, biotech, devices)
- Study start
- Nov 2004
- Study completion
- Sep 2007 (actual)
- First posted
- 26 Jan 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objectives of this study are to determine the safety and feasibility of inducing mild hypothermia using a non-invasive thermoregulatory device, the Medivance Arctic Sun Temperature Management System, in patients resuscitated after cardiac arrest.
Detailed description
Extensive research has been conducted in the use of mild hypothermia as a neuroprotectant in acute brain injury in animal models with studies having been initiated as far back as the 1950's. However, little work had been done in the area of therapeutic hypothermia and cardiac arrest.
In the early 80's, the Pittsburgh group resurrected the work with the induction of hypothermia in animals. The discovery of mild resuscitative hypothermia provided evidence that the main mechanism by which hypothermia can help resuscitate the brain after normothermic cardiac arrest is a synergistic effect of the suppression of deleterious chemical cascades, energy loss depolarization, calcium influx, excitotoxicity, free radical reactions, membrane failure, DNA fragmentation, and damage to the mitochondria).
Recently, the study "Mild hypothermia to improve the neurologic outcome after cardiac arrest" from the Hypothermia After Cardiac Arrest Study Group (New Engl J Med 2002;346:549-556) reported the results of a multicenter randomized controlled clinical trial that evaluated the effect of mild systemic hypothermia on mortality and functional outcome after resuscitation from out-of-hospital cardiac arrest due to ventricular fibrillation or tachycardia. Two hundred and seventy three patients were randomly assigned to standard normothermic or hypothermic management. Cooling to a target core body temperature of 32ºC to 34ºC was accomplished with the use of a specialized bed which delivers cold air over the entire body. Temperature was maintained in the target range for 24 hours after the start of cooling, followed by passive rewarming over 8 hours. Outcome was assessed at 6 months with a five point scale similar to the Glasgow Outcome Scale, dichotomized to classify independent patients with minimal or moderate disability to those who were dependent and severely disabled, vegetative, or dead. The results demonstrated a favorable neurological outcome in 55% of the 136 patients treated with hypothermia, compared to 39% of the 137 patients treated with normothermic management (risk ratio 1.40, 95% confidence interval 1.08 to 1.81, P=.009). . Mortality was also reduced with hypothermic management, from 41% in the hypothermia group to 55% in the normothermia group (risk ratio 0.74, 95% confidence interval 0.58 to 0.85, P=.02). In 19 patients (14%), the target temperature could not be reached. Complications did not differ significantly between the two groups, although there were trends toward increased rates of sepsis and bleeding with hypothermia.
Based upon the body of published evidence to date, the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR) made the following recommendations in October 2002 (Resuscitation 57 (2003) 231-235):
- Unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest should be cooled to 32-34°C for 12 -24 hours when the initial rhythm is ventricular fibrillation (VF).
- Such cooling may also be beneficial for other rhythms or in-hospital cardiac arrest
The study is a prospective, randomized, multi-center, pilot study of the Arctic Sun System used as adjunctive therapy in patients resuscitated post cardiac arrest.
Patients who meet the inclusion criteria and for whom informed consent has been provided by an authorized representative/family member will be randomly assigned to either the control group (traditional cooling blankets and ice) or the experimental group (Arctic Sun Temperature Management System).
Patients will be cooled to a target range of 33.5°C to 33.9°C. The patient cooling will continue for 24 hours (from the initiation of cooling) and then gradually rewarmed to 36.0°C over approximately 6 to 12 hours.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Male or female patients ≥ 18 years.
- Witnessed out-of-hospital cardiac arrest of presumed cardiac origin in which the initial rhythm is ventricular fibrillation, ventricular tachycardia, pulseless electrical activity (PEA) or asystole.
- First attempt at resuscitation (ACLS or CPR) by emergency medical personnel initiated within 15 minutes of collapse.
- Restoration of spontaneous circulation (ROSC) within 60 minutes of collapse.
- Time from restoration of spontaneous circulation to initiation of cooling is ≤ 6 hours.
Key exclusion criteria (17 listed)
- Temperature of less than 35C on admission.
- Comatose or vegetative state prior to cardiac arrest.
- Positive pregnancy test.
- Purposeful response to verbal commands after ROSC and prior to initiation of hypothermia.
- Evidence of hypotension (MAP<60) for more than 30 minutes after ROSC and prior to initiation of hypothermia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mild hypothermia | Device | – |
Primary outcome
Feasibility -patient temperature below 34C within 4 hours
Feasibility -maintain patient target temperature for 24 hrs
Safety - serious adverse events, mortality
1 secondary outcome
Effectiveness - neurological outcome measured by OPC/CPC
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2007.
- Derived from this study: PubMed 19854555Heard KJ, Peberdy MA, Sayre MR, Sanders A, Geocadin RG, Dixon SR, Larabee TM, Hiller K, Fiorello A, Paradis NA, O'Neil BJ. A randomized controlled trial comparing the Arctic Sun to standard cooling for induction of hypothermia after cardiac arrest. Resuscitation. 2010 Jan;81(1):9-14. doi: 10.1016/j.resuscitation.2009.09.015. Epub 2009 Oct 24.
Related trials for Cardiac Arrest
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
Active, not recruitingPhase 3
The Danish Out-of-Hospital Cardiac Arrest Study
Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
RecruitingObservational study
Evaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm
Cardiac Arrest (CA), Cardiogenic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kennon Heard, M.D. principal investigator
University of Colorado, Denver
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing mild hypothermia in people with Cardiac Arrest, run by Medivance, Inc. at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility -patient temperature below 34C within 4 hours. The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00282373, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2007.